2020 Pipeline Guide: Proto Oncogene Tyrosine Protein Kinase ROS - Therapeutics Development & Assessment, Companies Involved, Drug Profiles, Dormant Projects, Discontinued Products
DUBLIN, March 30, 2020 /PRNewswire/ -- The "Proto Oncogene Tyrosine Protein Kinase ROS - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
Proto Oncogene Tyrosine Protein Kinase ROS pipeline target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.
The report, Proto Oncogene Tyrosine Protein Kinase ROS - Pipeline Review, H1 2020 outlays comprehensive information on the Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Proto Oncogene Tyrosine Protein Kinase ROS targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II and Phase I stages are 1, 2, 3 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively.
Scope
-- The report provides a snapshot of the global therapeutic landscape for
Proto Oncogene Tyrosine Protein Kinase ROS
-- The report reviews Proto Oncogene Tyrosine Protein Kinase ROS targeted
therapeutics under development by companies and universities/research
institutes based on information derived from company and
industry-specific sources
-- The report covers pipeline products based on various stages of
development ranging from pre-registration till discovery and undisclosed
stages
-- The report features descriptive drug profiles for the pipeline products
which includes, product description, descriptive MoA, R&D brief,
licensing and collaboration details & other developmental activities
-- The report reviews key players involved in Proto Oncogene Tyrosine
Protein Kinase ROS targeted therapeutics and enlists all their major and
minor projects
-- The report assesses Proto Oncogene Tyrosine Protein Kinase ROS targeted
therapeutics based on mechanism of action (MoA), route of administration
(RoA) and molecule type
-- The report summarizes all the dormant and discontinued pipeline projects
-- The report reviews latest news and deals related to Proto Oncogene
Tyrosine Protein Kinase ROS targeted therapeutics
Key Topics Covered
1. Introduction
2. Report Coverage
3. Overview
4. Therapeutics Development
5. Products under Development by Stage of Development
6. Products under Development by Therapy Area
7. Products under Development by Indication
8. Products under Development by Companies
9. Products under Development by Universities/Institutes
10. Therapeutics Assessment
11. Assessment by Mechanism of Action
12. Assessment by Route of Administration
13. Assessment by Molecule Type
14. Companies Involved in Therapeutics Development
15. Drug Profiles
16. Dormant Products
17. Product Development Milestones
Featured News & Press Releases
-- Feb 21, 2020: Chugai obtains approval for additional indication of
Rozlytrek for ROS1 fusion-positive Non-Small Cell Lung Cancer
-- Jan 15, 2020: Crizotinib in NSCLC with a MET exon 14 alteration
-- Dec 26, 2019: Chugai obtains approval for expanded use of FoundationOne
CDx Cancer Genomic Profile as a companion diagnostic of Rozlytrek for
ROS1-positive Lung Cancer
-- Dec 13, 2019: Lancet Oncology: Entrectinib effective, well-tolerated
against ROS1 and NTRK lung cancers, especially with brain metastases
-- Nov 12, 2019: Turning Point Therapeutics initiates phase 1/2 clinical
study of Repotrectinib in pediatric patients
-- Nov 08, 2019: Crizotinib in c-MET- or ROS1-positive Non-Small Cell Lung
Cancer
-- Oct 30, 2019: European Society for Medical Oncology: Phase I/II study
results with Lorlatinib in ROS1-positive advanced NSCLC
-- Oct 29, 2019: Vanderbilt Oncologists publish results of first study to
demonstrate clinical utility of resolution liquid biopsy assay to
monitor response and resistance to Ensartinib
-- Oct 17, 2019: The Lancet Respiratory Medicine published study shows
Ensartinib holds promise as a new treatment option for ALK-positive
Non-Small Cell Lung Cancer (NSCLC)
-- Sep 25, 2019: Preclincal results of Baoyuan's next-generation ROS1/NTRK
inhibitor AB-106 published in Nature Communications
-- Sep 06, 2019: Chugai files for expanded use of FoundationOne CDx Cancer
Genomic Profile as a companion diagnostic of Rozlytrek for ROS1-positive
NSCLC
-- Sep 04, 2019: Chugai launches Rozlytrek, an Anticancer Agent for the
treatment of NTRK Fusion-Positive Solid Tumors
-- Sep 03, 2019: Turning Point Therapeutics announces updated interim
clinical data of Repotrectinib
-- Aug 21, 2019: ROZLYTREK (entrectinib), FDA approved for hard-to-treat
NTRK fusion-positive tumors, available at Biologics by McKesson
-- Aug 16, 2019: FDA approves Roche Rozlytrek (entrectinib) for people with
ROS1-positive, metastatic non-small cell lung cancer and NTRK gene
fusion-positive solid tumours
Companies Mentioned
-- AnHeart Therapeutics Inc
-- Ascentage Pharma Group International
-- Eli Lilly and Co
-- F. Hoffmann-La Roche Ltd
-- Pfizer Inc
-- Turning Point Therapeutics Inc
-- Xcovery Holding Company LLC
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/a2qlev
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
